Evidence-Based Complementary and Alternative Medicine / 2016 / Article / Tab 2 / Research Article
Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review Table 2 Quality assessment of the included studies.
Trials Randomization Concealment allocation Blinding of participants Blinding of outcome assessors Incomplete outcome data Selective reporting Other sources of bias Chen et al. [13 ] Unclear Unclear Unclear Unclear Low risk High risk Unclear Chen and Li [14 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Chen et al. [15 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Du [16 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Li et al. [17 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Liu et al. [18 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Liu et al. [19 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Liu et al. [20 ] Unclear Low risk Low risk Low risk Low risk Low risk Unclear Liu et al. [21 ] High risk Unclear Unclear Unclear Low risk Low risk Unclear Pang [22 ] Low risk Unclear Unclear Unclear Low risk Low risk Unclear Qi and Zhang [23 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Qin et al. [24 ] High risk Unclear Unclear Unclear Low risk Low risk Unclear Shao [25 ] Low risk Unclear Unclear Unclear Low risk Low risk Unclear Shi et al. [26 ] Unclear Low risk Low risk Low risk Low risk Low risk Unclear Sun et al. [27 ] Unclear Low risk Low risk Low risk Low risk Low risk Unclear Tu [28 ] Low risk Unclear Unclear Unclear Low risk Low risk Unclear Wu et al. [29 ] High risk Unclear Unclear Unclear Low risk High risk Unclear Yang et al. [30 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Zhang et al. [31 ] Unclear Unclear Unclear Unclear Low risk Low risk Unclear Niu et al. [32 ] High risk Unclear Unclear Unclear Low risk Low risk Unclear
